

# **Proteomics**

## **Part I: Technologies & Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**December 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant and CEO at Jain PharmaBiotech.

Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons. Both these books are now incorporated in a special report on gene therapy published in 2004 by Jain PharmaBiotech with the latest edition in 2015. His latest books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed 2017), Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012, 2<sup>nd</sup> ed 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2<sup>nd</sup> ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (January 2015).

## **A B O U T   T H I S   R E P O R T**

The proteomics report started as an expansion of the chapter on proteomics in Prof. Jain's report on "The Impact of Genomics on Drug Discovery and Development" published by Decision Resources Inc in 1999 and has been constantly updated since its publication as a separate report in 2000 by Jain PharmaBiotech. It has been rewritten several times since then.

**December 2017 (continuously published since 2000)**  
**Copyright © 2017 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:    +4161-6924461**  
**Email:        info@pharmabiotech.ch**  
**Web site:     http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>17</b>
<b>1. Basics of Proteomics.....</b>	<b>19</b>
<b>Introduction .....</b>	<b>19</b>
<b>History.....</b>	<b>19</b>
<b>Nucleic acids, genes and proteins .....</b>	<b>20</b>
Genome.....	20
DNA .....	21
RNA .....	21
<i>MicroRNAs .....</i>	<i>22</i>
<i>Decoding of mRNA by the ribosome .....</i>	<i>23</i>
Genes.....	23
Alternative splicing.....	23
Transcription.....	24
Gene regulation .....	25
Gene expression .....	25
Chromatin.....	26
Golgi complex.....	26
Proteins.....	27
<i>Functions of proteins .....</i>	<i>27</i>
<i>Proteasome.....</i>	<i>28</i>
<i>Spliceosome.....</i>	<i>28</i>
<i>Inter-relationship of protein, mRNA and DNA.....</i>	<i>29</i>
<b>Proteomics.....</b>	<b>30</b>
<b>Endoplasmic reticulum.....</b>	<b>31</b>
Mitochondrial proteome .....	31
<i>S-nitrosoproteins in mitochondria .....</i>	<i>32</i>
<b>Proteomics and genomics .....</b>	<b>32</b>
Classification of proteomics .....	35
Levels of functional genomics and various "omics" .....	35
Glycoproteomics .....	35
Transcriptomics .....	36
Metabolomics .....	36
Cytomics.....	36
<b>Phenomics .....</b>	<b>36</b>
<b>Impact of the genetic factors on the human proteome .....</b>	<b>37</b>
<b>Proteomics and systems biology.....</b>	<b>37</b>
<b>Proteomics and synthetic biology .....</b>	<b>38</b>
Functional synthetic proteins .....	38
Synthetic proteomics for study of apoptosis .....	39
<b>2. Proteomic Technologies.....</b>	<b>41</b>
<b>Key technologies driving proteomics .....</b>	<b>41</b>
<b>Sample preparation .....</b>	<b>42</b>
New trends in sample preparation .....	42
Pressure Cycling Technology .....	43
<b>Protein separation technologies .....</b>	<b>43</b>
High resolution 2DGE .....	43
Variations of 2D gel technology .....	44
Limitations of 2DGE and measures to overcome these .....	44
1-D sodium dodecyl sulfate (SDS) PAGE .....	44
Capillary electrophoresis systems.....	45
Head column stacking capillary zone electrophoresis .....	45
Removal of albumin and IgG .....	45
SeraFILE™ separations platform .....	46
Companies with protein separation technologies .....	46
<b>Protein purification.....</b>	<b>48</b>
Technologies for protein purification .....	48
Applications of protein purification .....	48
<b>Protein detection .....</b>	<b>48</b>
<b>Protein identification and characterization .....</b>	<b>49</b>
Mass spectrometry.....	49
<i>Electrospray ionization.....</i>	<i>49</i>
<i>Desorption electrospray ionization MS .....</i>	<i>51</i>
<i>Ion-mobility spectrometry-MS .....</i>	<i>51</i>
<i>Mirosaic 3500 MiD.....</i>	<i>52</i>
<i>Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry .....</i>	<i>52</i>

<i>Cryogenic MALDI- Fourier Transform Mass Spectrometry</i> .....	54
<i>Stable-isotope-dilution tandem mass spectrometry</i> .....	54
<i>HUPO Gold MS Protein Standard</i> .....	54
<i>Companies involved in mass spectrometry</i> .....	55
High performance liquid chromatography .....	55
Multidimensional protein identification technology (MudPIT) .....	56
Multiple reaction monitoring assays .....	56
Peptide mass fingerprinting .....	57
Current status and future prospects of clinical mass spectrometry .....	57
Combination of protein separation technologies with mass spectrometry .....	58
<i>Combining capillary electrophoresis with mass spectrometry</i> .....	58
<i>2D PAGE and mass spectrometry</i> .....	58
<i>Quantification of low abundance proteins</i> .....	59
<i>SDS-PAGE</i> .....	59
Antibodies and proteomics .....	59
Detection of fusion proteins .....	60
Labeling and detection of proteins .....	60
<i>Bioorthogonal non-canonical amino-acid-tagging techniques</i> .....	60
<i>Stable-isotope labeling of amino acids in cell culture</i> .....	60
<i>Fluorescent labeling of proteins in living cells</i> .....	61
<i>Combination of microspheres with fluorescence</i> .....	61
<i>Self-labeling protein tags</i> .....	62
Analysis of peptides .....	62
<i>C-terminal peptide analysis</i> .....	63
<i>Differential Peptide Display</i> .....	63
<i>Peptide analyses using NanoLC-MS</i> .....	64
<b>Protein sequencing</b> .....	<b>64</b>
<b>Real-time PCR for protein quantification</b> .....	<b>65</b>
<b>Quantitative proteomics</b> .....	<b>65</b>
MS-based quantitative proteomics .....	65
MS and cryo-electron tomography .....	66
Selected reaction monitoring MS .....	66
<b>Functional proteomics: technologies for studying protein function</b> .....	<b>66</b>
Functional genomics by mass spectrometry .....	66
LC-MS-based method for annotating the protein-coding genome .....	67
<b>RNA-Protein fusions</b> .....	<b>67</b>
<b>Designed repeat proteins</b> .....	<b>68</b>
<b>Application of nanobiotechnology to proteomics</b> .....	<b>68</b>
Nanoproteomics .....	68
<i>Nanoflow liquid chromatography</i> .....	68
<i>Nanopores for phosphoprotein analysis</i> .....	69
<i>Nanotube electronic biosensor for proteomics</i> .....	69
<i>Protein nanocrystallography</i> .....	69
<i>Single-molecule mass spectrometry using a nanopore</i> .....	70
<i>Nanoelectrospray ionization</i> .....	70
<i>Nanoproteomics for discovery of protein biomarkers in the blood</i> .....	70
<i>QD-protein nanoassembly</i> .....	71
Nanoparticle barcodes .....	71
<i>Biobarcode assay for proteins</i> .....	71
Nanopore-based protein sequencing .....	72
Nanoscale protein analysis .....	73
Nanoscale mechanism for protein engineering .....	73
Nanotube electronic biosensor .....	74
Nanotube-vesicle networks for study of membrane proteins .....	74
Qdot-nanocrystals .....	74
Resonance Light Scattering technology .....	75
Study of single membrane proteins at subnanometer resolution .....	75
<b>Protein expression profiling</b> .....	<b>75</b>
<b>Cell-based protein assays</b> .....	<b>76</b>
Living cell-based assays for protein function .....	77
Companies developing cell-based protein assays .....	77
<b>Protein function studies</b> .....	<b>78</b>
Transcriptionally Active PCR .....	78
Protein-protein interactions .....	78
<i>Bacterial protein interaction studies for assigning function</i> .....	80
<i>Bioluminescence Resonance Energy Transfer</i> .....	80
<i>Computational prediction of interactions</i> .....	80
<i>Detection Enhanced Ubiquitin Split Protein Sensor technology</i> .....	81
<i>Double Switch technology</i> .....	81
<i>Fluorescence Resonance Energy Transfer</i> .....	81
<i>In vivo study of protein-protein interactions</i> .....	82

<i>In vitro</i> study of protein-protein interactions .....	82
Interactome .....	82
Membrane 1-hybrid method .....	83
Nanowire transistor for the detection of protein-protein interactions.....	84
Phage display .....	84
Protein affinity chromatography.....	84
Protein-fragment complementation system .....	84
Proximity-dependent hybridization chain reaction .....	85
Yeast 2-hybrid system.....	85
Companies with technologies for protein-protein interaction studies .....	86
Protein-DNA interaction .....	87
<b>Determination of protein structure .....</b>	<b>87</b>
X-Ray crystallography .....	88
Nuclear magnetic resonance.....	88
Electron spin resonance .....	89
Prediction of protein structure .....	89
Protein tomography.....	90
X-ray scattering-based method for determining the structure of proteins.....	90
<b>Prediction of protein function .....</b>	<b>91</b>
Three-dimensional proteomics for determination of function.....	91
An algorithm for genome-wide prediction of protein function .....	92
Monitoring protein function by expression profiling.....	92
<b>Isotope-coded affinity tag peptide labeling .....</b>	<b>92</b>
<b>Differential Proteomic Panning .....</b>	<b>93</b>
<b>Cell map proteomics .....</b>	<b>93</b>
<b>Topological proteomics.....</b>	<b>93</b>
<b>Organelle or subcellular proteomics .....</b>	<b>94</b>
<b>Nucleolar proteomics.....</b>	<b>95</b>
<b>Glycoproteomic technologies.....</b>	<b>95</b>
High-sensitivity glycoprotein analysis .....	95
Fluorescent in vivo imaging of glycoproteins.....	96
<b>Integrated approaches for protein characterization .....</b>	<b>96</b>
<b>Imaging mass spectrometry .....</b>	<b>96</b>
IMS technologies .....	97
Applications of IMS .....	97
The protein microscope.....	98
Tag-Mass IMS.....	98
<b>Quantitative immunofluorescence for proteomics .....</b>	<b>98</b>
<b>Automation and robotics in proteomics .....</b>	<b>99</b>
<b>Western blot.....</b>	<b>99</b>
Limitations of WB.....	99
Innovations in WB.....	99
<i>Capillary electrophoresis and WB .....</i>	<i>100</i>
<i>Chemiluminescent western blotting .....</i>	<i>100</i>
<i>Fluorescent WB.....</i>	<i>101</i>
<i>Microfluidics and WB .....</i>	<i>101</i>
<i>Multiplexing WB.....</i>	<i>102</i>
Applications of Western blot .....	102
<i>Research applications of Western blot.....</i>	<i>102</i>
<i>Molecular diagnostic applications of Western blot.....</i>	<i>102</i>
Companies involved in Western blotting technologies .....	103
<b>Laser capture microdissection .....</b>	<b>104</b>
Microdissection techniques used for proteomics .....	104
Uses of LCM in combination with proteomic technologies .....	104
<b>Concluding remarks about applications of proteomic technologies.....</b>	<b>105</b>
NextGen Proteomics Platform .....	106
Precision proteomics .....	106
<b>3. Protein biochip technology .....</b>	<b>107</b>
<b>Introduction .....</b>	<b>107</b>
<b>Types of protein biochips.....</b>	<b>108</b>
ProteinChip .....	108
<i>Applications and advantages of ProteinChip.....</i>	<i>109</i>
<i>ProteinChip Biomarker System .....</i>	<i>109</i>
<i>Matrix-free ProteinChip Array .....</i>	<i>110</i>
Aptamer-based protein biochip .....	110
Fluorescence planar wave guide technology-based protein biochips.....	111
Lab-on-a-chip for protein analysis.....	111
Biochips for peptide arrays.....	112
Microfluidic biochips for proteomics .....	112
Protein biochips and microarrays for high-throughput expression .....	113

<i>Nucleic Acid-Programmable Protein Array</i> .....	113
<i>High-density protein microarrays</i> .....	113
<i>HPLC-Chip for protein identification</i> .....	114
<i>Antibody microarrays</i> .....	114
<i>HuProt™ Human Proteome Microarrays</i> .....	114
<i>Integration of protein array and image analysis</i> .....	115
<b>Tissue microarray technology for proteomics</b> .....	<b>115</b>
<b>Protein biochips in molecular diagnostics</b> .....	<b>115</b>
A force-based protein biochip .....	116
L1 chip and lipid immobilization .....	116
Multiplexed Protein Profiling on Microarrays.....	117
<b>Live cell microarrays</b> .....	<b>117</b>
<b>ProteinArray Workstation</b> .....	<b>118</b>
<b>Proteome arrays</b> .....	<b>118</b>
The Yeast ProtoArray .....	118
ProtoArray™ Human Protein Microarray .....	119
TRINECTIN proteome chip.....	119
<b>Peptide arrays</b> .....	<b>120</b>
<b>Surface plasmon resonance technology</b> .....	<b>120</b>
SPR Systems.....	120
FLEX CHIP.....	121
Combination of surface plasmon resonance and MALDI-TOF .....	121
<b>Protein chips/microarrays using nanotechnology</b> .....	<b>122</b>
Nanoparticle protein chip .....	122
Protein nanobiochip.....	122
Protein nanoarrays.....	123
Self-assembling protein nanoarrays.....	123
<b>Companies involved in protein biochip/microarray technology</b> .....	<b>123</b>
<b>4. Bioinformatics in Relation to Proteomics</b> .....	<b>127</b>
<b>Introduction</b> .....	<b>127</b>
<b>Bioinformatic tools for proteomics</b> .....	<b>127</b>
Testing of SELDI-TOF MS Proteomic Data.....	127
BioImagine's ProteinMine .....	128
<b>Bioinformatics for pharmaceutical applications of proteomics</b> .....	<b>128</b>
In silico search of drug targets by Biopendium.....	128
Compugen's LEADS .....	129
DrugScore.....	129
Proteochemometric modeling .....	129
<b>Integration of genomic and proteomic data</b> .....	<b>130</b>
<b>Proteomic databases: creation and analysis</b> .....	<b>131</b>
Introduction .....	131
Proteomic databases .....	131
<i>GenProtEC</i> .....	132
<i>Human Protein Atlas</i> .....	132
<i>Human Proteomics Initiative</i> .....	133
<i>Human proteome map</i> .....	134
<i>International Protein Index</i> .....	134
<i>MS-based draft of the human proteome</i> .....	134
<i>Protein Structure Initiative – Structural Genomics Knowledgebase</i> .....	134
<i>Protein Warehouse Database</i> .....	135
<i>Protein Data Bank</i> .....	135
<i>Repository for raw data from proteomics MS</i> .....	135
<i>Universal Protein Resource</i> .....	136
Protein interaction databases .....	136
<i>Biomolecular Interaction Network Database</i> .....	137
ENCODE .....	137
<i>Functional Genomics Consortium</i> .....	138
<i>Human Proteinpedia</i> .....	138
<i>ProteinCenter</i> .....	138
<i>Databases of the National Center for Biotechnology Information</i> .....	139
<b>Application of bioinformatics for protein identification</b> .....	<b>139</b>
Tandem MS for protein identification .....	139
Targeted MS for specific identification of proteins.....	139
<b>Application of bioinformatics in functional proteomics</b> .....	<b>140</b>
<b>Use of bioinformatics in protein sequencing</b> .....	<b>140</b>
Bottom-up protein sequencing.....	141
Top-down protein sequencing.....	142
Integration of next generation proteomics and gene sequencing data .....	142
<b>Protein structural database approach to drug design</b> .....	<b>142</b>
<b>Bioinformatics for high-throughput proteomics</b> .....	<b>143</b>

<b>Bioinformatics for protein-protein interactions.....</b>	<b>144</b>
<b>Companies with bioinformatic tools for proteomics .....</b>	<b>144</b>
<b>5. Research in Proteomics .....</b>	<b>147</b>
<b>Introduction .....</b>	<b>147</b>
<b>Applications of proteomics in biological research .....</b>	<b>147</b>
Identification of novel human genes by comparative proteomics .....	147
Study of relationship between genes and proteins.....	148
Characterization of histone codes.....	148
<b>Structural genomics or structural proteomics.....</b>	<b>149</b>
Protein Structure Factory .....	150
Protein Structure Initiative .....	150
Studies on protein structure at Argonne National Laboratory .....	151
Structural Genomics Consortium.....	151
<b>Protein knockout .....</b>	<b>152</b>
Antisense approach and proteomics .....	152
RNAi and protein knockout.....	152
Total knockout of cellular proteins.....	153
<b>Ribozymes and proteomics .....</b>	<b>153</b>
<b>Single molecule proteomics .....</b>	<b>153</b>
Single-molecule photon stamping spectroscopy .....	153
Single nucleotide polymorphism determination by TOF-MS.....	154
<b>Application of proteomic technologies in systems biology .....</b>	<b>154</b>
Signaling pathways and proteomics.....	155
Kinomics.....	155
Combinatorial RNAi for quantitative protein network analysis .....	155
<b>Proteomics in neuroscience research.....</b>	<b>156</b>
<b>Stem cell proteomics .....</b>	<b>156</b>
Comparative proteomic analysis of somatic cells, iPSCs and ESCs .....	157
hESC phosphoproteome.....	157
Proteomic studies of mesenchymal stem cells.....	157
Proteomics of neural stem cells.....	158
Proteome Biology of Stem Cells Initiative .....	158
<b>Proteomic analysis of the cell cycle .....</b>	<b>159</b>
<b>Nitric oxide and proteomics .....</b>	<b>159</b>
A proteomic method for identification of cysteine S-nitrosylation sites .....	159
Study of the nitroproteome .....	160
<b>Study of the phosphoproteome.....</b>	<b>160</b>
<b>Study of the mitochondrial proteome .....</b>	<b>161</b>
Proteomic technologies for study of mitochondrial proteomics .....	161
<b>Cryptome.....</b>	<b>162</b>
<b>Study of protein transport in health and disease .....</b>	<b>162</b>
<b>Ancient proteomics .....</b>	<b>162</b>
<b>Proteomics research in the academic sector .....</b>	<b>163</b>
Netherlands Proteins@Work .....	165
ProteomeBinders initiative.....	165
Rutgers University's Center for Integrative Proteomics Research.....	165
Vanderbilt University's Center for Proteomics and Drug Actions .....	166
<b>6. Pharmaceutical Applications of Proteomics .....</b>	<b>167</b>
<b>Introduction .....</b>	<b>167</b>
<b>Current drug discovery process and its limitations .....</b>	<b>167</b>
<b>Role of omics in drug discovery .....</b>	<b>168</b>
Genomics-based drug discovery.....	168
Metabolomics technologies for drug discovery .....	169
Role of metabolomics in drug discovery .....	169
Basis of proteomics approach to drug discovery.....	170
<i>Proteins and drug action .....</i>	<i>170</i>
<i>Transcription-aided drug design.....</i>	<i>171</i>
In vivo production of therapeutic proteins by mRNA .....	171
Role of proteomic technologies in drug discovery .....	171
<i>Liquid chromatography-based drug discovery .....</i>	<i>172</i>
<i>Capture compound mass spectrometry .....</i>	<i>172</i>
<i>Protein-expression mapping by 2DGE.....</i>	<i>172</i>
<i>Protein-protein interactions and drug discovery .....</i>	<i>173</i>
<i>Role of MALDI mass spectrometry in drug discovery.....</i>	<i>173</i>
<i>Structural proteomics and drug discovery .....</i>	<i>174</i>
<i>Tissue imaging mass spectrometry.....</i>	<i>174</i>
Oxford Genome Anatomy Project .....	176
Proteins as drug targets.....	176
<i>Monitoring drug target binding using the cellular thermal shift assay .....</i>	<i>176</i>

Ligands to capture the purine binding proteome .....	176
Chemical probes to interrogate key protein families for drug discovery .....	177
Global proteomics for pharmacodynamics .....	177
ProteoCarta® proteomics platform .....	178
ZeptoMARK™ protein profiling system .....	178
<b>Role of proteomics in targeting disease pathways .....</b>	<b>179</b>
Dynamic proteomics .....	179
Identification of protein kinases as drug targets .....	179
<i>Mechanisms of action of kinase inhibitors</i> .....	180
G-protein coupled receptors as drug targets .....	180
<i>Methods of study of GPCRs</i> .....	181
<i>Cell-based assays for GPCR</i> .....	181
<i>Companies involved in GPCR-based drug discovery</i> .....	182
<i>GPCR localization database</i> .....	183
Matrix metalloproteases as drug targets .....	183
PDZ proteins as drug targets .....	183
Proteasome as drug target .....	184
Serine hydrolases as drug targets .....	185
Targeting mTOR signaling pathway .....	185
Targeting caspase-8 for anticancer therapeutics .....	186
<b>Drug design based on structural proteomics .....</b>	<b>187</b>
Protein crystallography for determining 3D structure of proteins .....	187
Automated 3D protein modeling .....	187
<i>Drug targeting of flexible dynamic proteins</i> .....	187
Companies involved in structure-based drug-design .....	188
<b>Integration of genomics and proteomics for drug discovery .....</b>	<b>189</b>
<b>Ligand-receptor binding .....</b>	<b>190</b>
Role of proteomics in study of ligand-receptor binding .....	190
<i>Measuring drug binding of proteins</i> .....	190
Aptamer protein binding .....	190
<i>Systematic Evolution of Ligands by Exponential Enrichment</i> .....	191
<i>Aptamers and high-throughput screening</i> .....	191
<i>Nucleic Acid Biotoools</i> .....	192
<i>Aptamer beacons</i> .....	192
<i>Peptide aptamers</i> .....	192
<b>Riboreporters for drug discovery .....</b>	<b>193</b>
<b>Target identification and validation .....</b>	<b>193</b>
Application of mass spectrometry for target identification .....	194
Gene knockout and gene suppression for validating protein targets .....	194
Laser-mediated protein knockout for target validation .....	194
<b>Integrated proteomics for drug discovery .....</b>	<b>195</b>
<b>High-throughput proteomics .....</b>	<b>195</b>
Companies involved in high-throughput proteomics .....	195
<b>Drug discovery through protein-protein interaction studies .....</b>	<b>196</b>
Protein-protein interaction as basis for drug target identification .....	197
Protein-PCNA interaction as basis for drug design .....	197
Two-hybrid protein interaction technology for target identification .....	198
Biosensors for detection of small molecule-protein interactions .....	198
Protein-protein interaction maps .....	199
<i>ProNet (Myriad Genetics)</i> .....	199
<i>Hybrigenics' maps of protein-protein interactions</i> .....	199
<i>CellZome's functional map of protein-protein interactions</i> .....	200
Mapping of protein-protein interactions by mass spectrometry .....	200
Protein interaction map of <i>Drosophila melanogaster</i> .....	201
Protein-interaction map of Wellcome Trust Sanger Institute .....	201
Protein-protein interactions as targets for therapeutic intervention .....	201
Inhibition of protein-protein interactions by peptide aptamers .....	202
Selective disruption of proteins by small molecules .....	202
<b>Post-genomic combinatorial biology approach .....</b>	<b>202</b>
<b>Differential proteomics .....</b>	<b>203</b>
<b>Shotgun proteomics .....</b>	<b>203</b>
<b>Targeted proteomics .....</b>	<b>204</b>
<b>Chemogenomics/chemoproteomics for drug discovery .....</b>	<b>204</b>
<i>Chemoproteomics-based drug discovery</i> .....	205
<i>Companies involved in chemogenomics/chemoproteomics</i> .....	205
<i>Activity-based proteomics</i> .....	207
<i>Locus Discovery technology</i> .....	207
<i>Automated ligand identification system</i> .....	207
<b>Expression proteomics: protein level quantification .....</b>	<b>208</b>
<b>Role of phage antibody libraries in target discovery .....</b>	<b>209</b>
<b>Analysis of posttranslational modification of proteins by MS .....</b>	<b>209</b>



<b>Phosphoproteomics for drug discovery</b> .....	<b>210</b>
<b>Application of glycoproteomics for drug discovery</b> .....	<b>210</b>
Role of carbohydrates in proteomics.....	210
Challenges of glycoproteomics.....	210
Companies involved in glycoproteomics .....	211
<b>Role of protein microarrays/ biochips for drug discovery</b> .....	<b>212</b>
Protein microarrays vs DNA microarrays for high-throughput screening .....	212
BIA-MS biochip for protein-protein interactions.....	212
ProteinChip with Surface Enhanced Neat Desorption.....	213
Protein-domains microarrays.....	213
Some limitations of protein biochips .....	213
<b>Concluding remarks about role of proteomics in drug discovery</b> .....	<b>214</b>
<b>RNA versus protein profiling as guide to drug development</b> .....	<b>214</b>
RNA as drug target .....	214
Combination of RNA and protein profiling .....	215
<i>RNA binding proteins</i> .....	216
<b>Toxicoproteomics</b> .....	<b>216</b>
Hepatotoxicity .....	216
Nephrotoxicity .....	217
Cardiotoxicity .....	217
Neurotoxicity.....	218
<b>Protein/peptide therapeutics</b> .....	<b>218</b>
Alphabody technology for improving protein therapeutics.....	218
Peptide-based drugs.....	218
Phylomer® peptides.....	219
Cryptein-based therapeutics.....	219
Synthetic proteins and peptides as pharmaceuticals .....	220
<b>Genetic immunization and proteomics</b> .....	<b>220</b>
<b>Role of proteomics in synthetic antivenoms</b> .....	<b>221</b>
<b>Proteomics and gene therapy</b> .....	<b>221</b>
<b>Role of proteomics in clinical drug development</b> .....	<b>222</b>
Pharmacoproteomics .....	222
Role of proteomics in clinical drug safety.....	222
<b>7. Application of Proteomics in Human Healthcare</b> .....	<b>225</b>
<b>Introduction</b> .....	<b>225</b>
<b>Clinical proteomics</b> .....	<b>226</b>
Definition and standards .....	226
Vermillion's Clinical Proteomics Program .....	226
<b>Pathophysiology of human diseases</b> .....	<b>227</b>
Diseases due to misfolding of proteins .....	227
<i>Mechanism of protein folding</i> .....	228
<i>Nanoproteomics for study of misfolded proteins</i> .....	229
<i>Therapies for protein misfolding</i> .....	229
Intermediate filament proteins .....	230
Significance of mitochondrial proteome in human disease .....	230
<i>Proteome of Saccharomyces cerevisiae mitochondria</i> .....	231
<i>Rat mitochondrial proteome</i> .....	231
<b>Proteomic approaches to biomarker identification</b> .....	<b>232</b>
The ideal biomarker .....	232
Proteomic technologies for biomarker discovery.....	232
<i>MALDI mass spectrometry for biomarker discovery</i> .....	233
Protein biochips/microarrays and biomarkers .....	233
Affinity proteomics for discovery of biomarkers.....	233
<i>Antibody array-based biomarker discovery</i> .....	234
<i>Discovery of biomarkers by MAb microarray profiling</i> .....	235
Tumor-specific serum peptidome patterns.....	235
Search for protein biomarkers in body fluids.....	235
Challenges and strategies for discovery of protein biomarkers in plasma.....	235
<i>3-D structure of CD38 as a biomarker</i> .....	237
<i>BD™ Free Flow Electrophoresis System</i> .....	237
<i>Isotope tags for relative and absolute quantification</i> .....	237
<i>N-terminal peptide isolation from human plasma</i> .....	238
<i>Plasma protein microparticles as biomarkers</i> .....	238
<i>Proteome partitioning</i> .....	238
<i>SISCAPA method for quantitating proteins and peptides in plasma</i> .....	239
<i>Stable isotope tagging methods</i> .....	239
<i>Technology to measure both the identity and size of the biomarker</i> .....	239
Biomarkers in the urinary proteome .....	240
<b>Application of proteomics in molecular diagnosis</b> .....	<b>240</b>
MassARRAY .....	241

Proximity ligation assay .....	242
Protein patterns .....	242
Proteomic tests on body fluids .....	242
Cyclical amplification of proteins .....	244
<b>Applications of proteomics in infections .....</b>	<b>244</b>
MALDI-TOF MS for microbial identification .....	244
Recognition of microbial glycans by human lectins .....	245
Role of proteomics in virology .....	245
<i>Interaction of proteins with viruses</i> .....	246
<i>Quantitative temporal viromics</i> .....	246
Role of proteomics in bacteriology .....	246
<i>Epidemiology of bacterial infections</i> .....	247
<i>Proteomic approach to bacterial pathogenesis</i> .....	247
<i>Vaccines for bacterial infections</i> .....	247
<i>Protein profiles associated with bacterial drug resistance</i> .....	248
Analyses of the parasite proteome .....	248
<b>Application of proteomics in cystic fibrosis .....</b>	<b>249</b>
<b>Proteomics of cardiovascular diseases .....</b>	<b>249</b>
Pathomechanism of cardiovascular diseases .....	249
Protein misfolding in cardiac dysfunction .....	250
Study of cardiac mitochondrial proteome in myocardial ischemia .....	250
Cardiac protein databases .....	250
Proteomics of dilated cardiomyopathy and heart failure .....	251
Proteomic biomarkers of cardiovascular diseases .....	251
Regulation of cardiac rhythmicity by Purkinje cell protein-4 .....	252
Role of proteomics in cardioprotection .....	252
Role of proteomics in heart transplantation .....	252
Future of application of proteomics in cardiology .....	253
<b>Proteomic technologies for research in pulmonary disorders .....</b>	<b>253</b>
<b>Application of proteomics in renal disorders .....</b>	<b>254</b>
Diagnosis of renal disorders .....	255
Proteomic biomarkers of acute kidney injury .....	255
Cystatin C as biomarker of glomerular filtration rate .....	255
Protein biomarkers of nephritis .....	255
Proteomics and kidney stones .....	256
<b>Proteomics of eye disorders .....</b>	<b>256</b>
Proteomics of cataract .....	257
Proteomics of diabetic retinopathy .....	257
Retinal dystrophies .....	257
<b>Use of proteomics in inner ear disorders .....</b>	<b>258</b>
<b>Use of proteomics in aging research .....</b>	<b>258</b>
Alteration of glycoproteins during aging .....	259
Carbamylation of proteins with aging .....	259
Proteomics of muscle aging .....	259
Removal of altered cellular proteins in aging .....	260
Role of protein aggregation in aging and degenerative diseases .....	260
Study of the role of Parkin in modulating aging .....	261
Study of proteins that protect against hypoxic injury in age-related disorders .....	261
<b>Proteomics and nutrition .....</b>	<b>261</b>
<b>8. Oncoproteomics .....</b>	<b>263</b>
<b>Introduction .....</b>	<b>263</b>
<b>Proteomic technologies for study of cancer .....</b>	<b>264</b>
Application of CellCarta technology for oncology .....	264
Accentuation of differentially expressed proteins using phage technology .....	264
Cancer tissue proteomics .....	264
<i>Dynamic cell proteomics in response to a drug</i> .....	265
Desorption electrospray ionization for cancer diagnosis .....	265
Id proteins as targets for cancer therapy .....	266
Identification of oncogenic tyrosine kinases using phosphoproteomics .....	266
Laser capture microdissection technology and cancer proteomics .....	266
Mass spectrometry for identification of oncogenic chimeric proteins .....	267
Proteomic analysis of cancer cell mitochondria .....	267
Proteomic study of p53 .....	268
Human Tumor Gene Index .....	268
Integration of cancer genomics and proteomics .....	268
Role of proteomics in study of cancer stem cell biology .....	269
Single-cell protein expression analysis by microfluidic techniques .....	269
<b>Use of proteomics in cancers of various organ systems .....</b>	<b>269</b>
Proteomics of brain tumors .....	269
<i>Malignant glial tumors</i> .....	269

<i>Meningiomas</i> .....	270
<i>DESI-MS for intraoperative diagnosis of brain tumors</i> .....	270
Proteomics of breast cancer .....	271
<i>Integration of proteomic and genomic data for breast cancer</i> .....	272
Proteomics of colorectal cancer.....	273
Proteomics of esophageal cancer .....	273
Proteomics of hepatic cancer .....	274
Proteomics of leukemia.....	274
Proteomics of lung cancer .....	275
Proteomics of pancreatic cancer.....	276
Proteomics of prostate cancer.....	276
Proteomics of renal cancer .....	277
<b>Diagnostic use of cancer biomarkers .....</b>	<b>277</b>
Proteomic technologies for tumor biomarkers .....	278
Nuclear matrix proteins (NMPs) .....	278
Antiannexins as tumor markers in lung cancer.....	279
<b>NCI's Network of Clinical Proteomic Technology Centers.....</b>	<b>279</b>
<b>Proteomics and tumor immunology .....</b>	<b>280</b>
<b>Proteomics and study of tumor invasiveness .....</b>	<b>280</b>
<b>Anticancer drug discovery and development .....</b>	<b>281</b>
Anticancer drug targeting: functional proteomics screen of proteases .....	281
Kinase-targeted drug discovery in oncology.....	281
Protein-drug interactions in cancer .....	282
Role of proteomics in studying drug resistance in cancer.....	282
Small molecule inhibitors of cancer-related proteins .....	283
<b>Future prospects of oncoproteomics.....</b>	<b>283</b>
International oncoproteomic initiatives .....	283
<i>Clinical Proteomic Tumor Analysis Consortium</i> .....	284
<b>Companies involved in application of proteomics to oncology .....</b>	<b>285</b>

<b>9. Neuroproteomics .....</b>	<b>287</b>
Introduction .....	287
Application of proteomics for the study of nervous system .....	287
<b>Proteomics of prion diseases .....</b>	<b>288</b>
Normal function of prions in the brain.....	288
Diseases due to pathological prion protein .....	288
Transmissible spongiform encephalopathies .....	289
<i>Creutzfeld-Jakob disease</i> .....	289
<i>Bovine spongiform encephalopathy</i> .....	289
<i>Variant Creutzfeldt-Jakob disease</i> .....	290
<b>Protein misfolding and neurodegenerative disorders.....</b>	<b>290</b>
Ion channel link for protein-misfolding disease .....	290
Detection of misfolded proteins.....	291
Modulation of proteostasis in neurodegenerative disorders .....	291
Neurodegenerative disorders with protein abnormalities .....	291
<i>Alzheimer disease</i> .....	293
<i>Common denominators of Alzheimer and prion diseases</i> .....	294
<i>Parkinson disease</i> .....	294
<i>Amyotrophic lateral sclerosis</i> .....	295
Proteomics and glutamate repeat disorders .....	295
<i>Proteomics and Huntington's disease</i> .....	296
<b>Proteomics and demyelinating diseases .....</b>	<b>297</b>
<b>Proteomics of neurogenetic disorders .....</b>	<b>297</b>
Fabry disease .....	297
GM1 gangliosidosis.....	297
Quantitative proteomics and familial hemiplegic migraine .....	298
Proteomics of spinal muscular atrophy.....	298
<b>Proteomics of CNS trauma .....</b>	<b>299</b>
Proteomics of traumatic brain injury .....	299
Chronic traumatic encephalopathy and ALS .....	300
<b>Proteomics of cerebrovascular disease.....</b>	<b>300</b>
Pathogenesis of cerebral small vessel disease.....	300
<b>Proteomics of CNS aging.....</b>	<b>301</b>
Protein aggregation as a biomarker of aging.....	301
<b>Neuroproteomics of psychiatric disorders.....</b>	<b>302</b>
Schizophrenia.....	302
Anxiety disorders .....	302
Depression and suicidal behavior.....	302
Neuroproteomic of cocaine addiction .....	303
<b>Neurodiagnostics based on proteomics.....</b>	<b>303</b>
Disease-specific proteins in the cerebrospinal fluid .....	303

<i>Tau proteins</i> .....	304
CNS tissue proteomics.....	305
Diagnosis of CNS disorders by examination of proteins in urine.....	306
Diagnosis of CNS disorders by examination of proteins in the blood.....	306
<i>Serum pNF-H as biomarker of CNS damage</i> .....	307
Intraoperative application of proteomics in surgery of brain tumors.....	307
<b>Proteomics of BBB</b> .....	<b>308</b>
<b>Future of neuroproteomics in neurology</b> .....	<b>308</b>
HUPO's Pilot Brain Proteome Project.....	309
<b>10. Proteomics Markets</b> .....	<b>311</b>
<b>Introduction</b> .....	<b>311</b>
<b>Potential markets for proteomic technologies</b> .....	<b>311</b>
Bioinformatics markets for proteomics.....	312
Markets for protein separation technologies.....	312
<i>Markets for 2D gel electrophoresis</i> .....	312
<i>Market trends in protein separation technologies</i> .....	312
Protein purification markets.....	313
Mass spectrometry markets.....	313
Markets for MALDI for drug discovery.....	313
Markets for nuclear magnetic resonance spectroscopy.....	314
Market for structure-based drug design.....	314
Markets for protein biomarkers.....	314
Markets for cell-based protein assays.....	314
Protein biochip markets.....	315
Western blot markets.....	315
Geographical distribution of proteomics technologies markets.....	315
<b>Business and strategic considerations</b> .....	<b>316</b>
Cost of protein structure determination.....	316
Opinion surveys of the scientist consumers of proteomic technologies.....	316
<i>Opinions on mass spectrometry</i> .....	316
<i>Opinions on bioinformatics and proteomic databases</i> .....	316
<i>Systems for in vivo study of protein-protein interactions</i> .....	316
<i>Perceptions of the value of protein biochip/microfluidic systems</i> .....	317
Small versus big companies.....	317
Expansion in proteomics according to area of application.....	317
Growth trends in cell-based protein assay market.....	317
<i>Challenges for development of cell-based protein assays</i> .....	318
<i>Future trends and prospects of cell-based protein assays</i> .....	318
Strategic collaborations.....	319
<i>Analysis of proteomics collaborations according to types of companies</i> .....	319
<i>Types of proteomic collaborations</i> .....	319
<i>Proteomics collaborations according to application areas</i> .....	320
<i>Analysis of proteomics collaborations: types of technologies</i> .....	320
<i>Collaborations based on protein biochip technology</i> .....	321
<i>Concluding remarks about proteomic collaborations</i> .....	321
Proteomic patents.....	322
<b>Market drivers in proteomics</b> .....	<b>322</b>
Needs of the pharmaceutical industry.....	322
Need for outsourcing proteomic technologies.....	323
Funding of proteomic companies and research.....	323
Technical advances in proteomics.....	323
Changing trends in healthcare in future.....	324
<b>Challenges facing proteomics</b> .....	<b>324</b>
Magnitude and complexity of the task.....	324
Technical challenges.....	324
Limitations of proteomics.....	325
<i>Limitations of 2DGE</i> .....	325
<i>Limitations of mass spectrometry techniques</i> .....	325
<i>Complexity of the pharmaceutical proteomics</i> .....	325
Unmet needs in proteomics.....	326
<b>11. Future of Proteomics</b> .....	<b>327</b>
<b>Genomics to proteomics</b> .....	<b>327</b>
Faster technologies.....	327
FLEXGene repository.....	327
<b>Need for new proteomic technologies</b> .....	<b>328</b>
<b>Emerging proteomic technologies</b> .....	<b>329</b>
Detection of alternative protein isoforms.....	329
Direct protein identification in large genomes by mass spectrometry.....	329
Proteome identification kits with stacked membranes.....	329

Vacuum deposition interface.....	330
In vitro protein biosynthesis.....	330
Proteome mining with adenosine triphosphate.....	330
Proteome-scale purification of human proteins from bacteria.....	330
Proteostasis network.....	331
Cytoproteomics.....	331
<i>Subcellular proteomics</i> .....	331
<i>Individual cell proteomics</i> .....	332
<i>Live cell proteomics</i> .....	332
<i>Fluorescent proteins for live-cell imaging</i> .....	333
Membrane proteomics.....	333
<i>Identification of membrane proteins by tandem MS of protein ions</i> .....	333
<i>Solid state NMR for study of nanocrystalline membrane proteins</i> .....	334
Multiplex proteomics.....	334
High-throughput for proteomics.....	334
Future directions for protein biochip application.....	335
Bioinformatics for proteomics.....	335
High-Throughput Crystallography Consortium.....	335
Study of protein folding by IBM's Blue Gene.....	336
Study of proteins by atomic force microscopy.....	336
<b>Population proteomics.....</b>	<b>336</b>
<b>Comparative proteome analysis.....</b>	<b>337</b>
<b>Human Proteome Organization.....</b>	<b>337</b>
Cell-based Human Proteome Project.....	338
<b>Human Salivary Proteome.....</b>	<b>338</b>
<b>Academic-commercial collaborations in proteomics.....</b>	<b>339</b>
Indiana Centers for Applied Protein Sciences.....	339
<b>Role of proteomics in the healthcare of the future.....</b>	<b>339</b>
Proteomics and molecular medicine.....	339
Proteodiagnostics.....	340
Proteomics and personalized medicine.....	340
<i>Targeting the ubiquitin pathway for personalized therapy of cancer</i> .....	341
<i>Protein patterns and personalized medicine</i> .....	341
<i>Personalizing interferon therapy of hepatitis C virus</i> .....	342
<i>Protein biochips and personalized medicine</i> .....	343
<i>Combination of diagnostics and therapeutics</i> .....	343
<i>Future prospects</i> .....	343
<b>12. References.....</b>	<b>345</b>

## Tables

Table 1-1: Landmarks in the evolution of proteomics.....	19
Table 1-2: Comparison of DNA and protein.....	29
Table 1-3: Comparison of mRNA and protein.....	29
Table 1-4: Methods of analysis at various levels of functional genomics.....	35
Table 2-1: Proteomics technologies.....	41
Table 2-2: Protein separation technologies of selected companies.....	46
Table 2-3: Companies supplying mass spectrometry instruments.....	55
Table 2-4: Companies involved in cell-based protein assays.....	77
Table 2-5: Methods used for the study of protein-protein interactions.....	79
Table 2-6: A selection of companies involved in protein-protein interaction studies.....	86
Table 2-7: Companies involved in Western blotting.....	103
Table 2-8: Proteomic technologies used with laser capture microdissection.....	104
Table 3-1: Applications of protein biochip technology.....	107
Table 3-2: Selected companies involved in protein biochip/microarray technology.....	123
Table 4-1: Proteomic databases and other Internet sources of proteomics information.....	131
Table 4-2: Protein interaction databases available on the Internet.....	137
Table 4-3: Bioinformatic tools for proteomics from academic sources.....	143
Table 4-4: Selected companies involved in bioinformatics for proteomics.....	144
Table 5-1: Applications of proteomics in basic biological research.....	147
Table 5-2: A sampling of proteomics research projects in academic institutions.....	163
Table 6-1: Pharmaceutical applications of proteomics.....	167
Table 6-2: Selected companies relevant to MALDI-MS for drug discovery.....	173
Table 6-3: Selected companies involved in GPCR-based drug discovery.....	182
Table 6-4: Companies involved in drug design based on structural proteomics.....	188
Table 6-5: Proteomic companies with high-throughput protein expression technologies.....	196
Table 6-6: Selected companies involved in chemogenomics/chemoproteomics.....	206
Table 6-7: Companies involved in glycoproteomic technologies.....	211
Table 7-1: Applications of proteomics in human healthcare.....	225

Table 7-2: Eye disorders and proteomic approaches.....	256
Table 8-1: Large scale international oncoproteomic initiatives .....	284
Table 8-2: Companies involved in applications of proteomics to oncology .....	285
Table 9-1: Neurodegenerative diseases with underlying protein abnormality .....	291
Table 9-2: Disease-specific proteins in the cerebrospinal fluid of patients.....	303
Table 10-1: Potential markets for proteomic technologies 2016-2026.....	311
Table 10-2: Geographical distribution of markets for proteomic technologies 2016-2026 .....	315
Table 11-1: Role of proteomics in personalizing strategies for cancer therapy .....	341

## Figures

Figure 1-1: A schematic miRNA pathway .....	22
Figure 1-2: Relationship of DNA, RNA and protein in the cell.....	30
Figure 1-3: Protein production pathway from gene expression to functional protein with controls. ....	33
Figure 1-4: Parallels between functional genomics and proteomics.....	33
Figure 2-1: Proteomics: flow from sample preparation to characterization.....	42
Figure 2-2: The central role of spectrometry in proteomics .....	49
Figure 2-3: Electrospray ionization (ESI) .....	50
Figure 2-4: Ion-mobility spectrometry-MS .....	51
Figure 2-5: Matrix-Assisted Laser Desorption/Ionization (MALDI).....	53
Figure 2-6: Scheme of bio-bar-code assay .....	72
Figure 2-7: A diagrammatic presentation of yeast 2-hybrid system .....	85
Figure 3-1: ProteinChip System .....	109
Figure 3-2: Surface plasma resonance (SPR).....	121
Figure 4-1: Role of bioinformatics in integrating genomic/proteomic-based drug discovery .....	130
Figure 4-2: Bottom-up and top-down approaches for protein sequencing .....	141
Figure 6-1: Drug discovery process.....	168
Figure 6-2: Regulatory changes induced by drugs and implemented at the proteins level. ....	170
Figure 6-3: Relation of proteome to genome, diseases and drugs .....	171
Figure 6-4: The mTOR pathways .....	186
Figure 6-5: Steps in shotgun proteomics .....	203
Figure 6-6: Chemogenomic approach to drug discovery (3-Dimensional Pharmaceuticals) .....	205
Figure 8-1: Relation of oncoproteomics to other technologies .....	263
Figure 9-1: A scheme of proteomics applications in CNS drug discovery and development .....	309
Figure 10-1: Types of companies involved in proteomics collaborations .....	319
Figure 10-2: Types of collaborations: R & D, licensing or marketing .....	320
Figure 10-3: Proteomics collaborations according to application areas .....	320
Figure 10-4: Proteomics collaborations according to technologies .....	321
Figure 10-5: Unmet needs in proteomics .....	326
Figure 11-1: A scheme of the role of proteomics in personalized management of cancer.....	342